Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report sent to investors on Friday morning. The firm issued a hold rating on the stock.

Separately, Cantor Fitzgerald reaffirmed a neutral rating and set a $3.30 target price on shares of Aspira Women’s Health in a report on Wednesday, April 10th.

Aspira Women’s Health Price Performance

Shares of AWH opened at $3.21 on Friday. The stock has a market capitalization of $39.61 million, a PE ratio of -0.27 and a beta of 1.57. The business’s fifty day moving average price is $3.44 and its 200 day moving average price is $3.93. Aspira Women’s Health has a 12-month low of $2.31 and a 12-month high of $6.75.

Aspira Women’s Health (NASDAQ:AWH) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.09. Aspira Women’s Health had a negative net margin of 176.74% and a negative return on equity of 1,099.32%. The company had revenue of $2.13 million for the quarter, compared to the consensus estimate of $2.70 million. As a group, research analysts anticipate that Aspira Women’s Health will post -1.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Northeast Financial Consultants Inc bought a new stake in shares of Aspira Women’s Health during the third quarter valued at approximately $126,000. Perkins Capital Management Inc. acquired a new stake in Aspira Women’s Health in the 3rd quarter valued at approximately $268,000. Quantum Private Wealth LLC raised its stake in Aspira Women’s Health by 76.8% during the 4th quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock valued at $205,000 after acquiring an additional 21,788 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. boosted its position in Aspira Women’s Health by 39.0% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 125,374 shares of the company’s stock worth $672,000 after acquiring an additional 35,177 shares during the period. 12.19% of the stock is owned by institutional investors and hedge funds.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.